Modelling drug transport during intraperitoneal chemotherapy
暂无分享,去创建一个
Patrick Segers | Wim Ceelen | Charlotte Debbaut | Margo Steuperaert | P. Segers | C. Debbaut | W. Ceelen | Margo Steuperaert
[1] Jerry Goodisman,et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[2] Greg M. Thurber,et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.
[3] Chi-Hwa Wang,et al. Chemotherapeutic drug transport to brain tumor. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[4] M F Flessner,et al. A distributed model of peritoneal-plasma transport: theoretical considerations. , 1984, The American journal of physiology.
[5] Beom Soo Shin,et al. Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy , 2009, Journal of Pharmacology and Experimental Therapeutics.
[6] Jörgen Carlsson,et al. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids , 2004, Cancer Chemotherapy and Pharmacology.
[7] J. Verweij,et al. Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. , 1994, British Journal of Cancer.
[8] Ze Lu,et al. Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel , 2007, Pharmaceutical Research.
[9] M D'Incalci,et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer , 2014, British Journal of Cancer.
[10] Robert J. Gillies,et al. Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor Tissues , 2013, Front. Oncol..
[11] Masaki Kitajima,et al. Antitumor activity of cis‐diamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro , 1995, Journal of surgical oncology.
[12] Donald E Mager,et al. Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[13] S Pili-Floury,et al. Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study , 2011, British Journal of Cancer.
[14] Vittorio Cristini,et al. Multiscale cancer modeling. , 2010, Annual review of biomedical engineering.
[15] Yuichi Sugiyama,et al. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product , 2004, Cancer Chemotherapy and Pharmacology.
[16] Chi-Hwa Wang,et al. Simulation of the Delivery of Doxorubicin to Hepatoma , 2001, Pharmaceutical Research.
[17] An Vermeulen,et al. A Model Based Analysis of IPEC Dosing of Paclitaxel in Rats , 2014, Pharmaceutical Research.
[18] R K Jain,et al. Haemodynamic and transport barriers to the treatment of solid tumours. , 1991, International journal of radiation biology.
[19] Jacek Waniewski,et al. Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. , 2012, American journal of physiology. Renal physiology.
[20] Ze Lu,et al. Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.
[21] H. Kampinga,et al. Reduction of cellular cisplatin resistance by hyperthermia--a review. , 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[22] H. Eichholtz-Wirth,et al. Heat sensitization to cisplatin in two cell lines with different drug sensitivities. , 1990, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[23] M. Flessner,et al. The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.
[24] W R Greco,et al. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.
[25] R. Dedrick,et al. Theoretical and experimental bases of intraperitoneal chemotherapy. , 1985, Seminars in oncology.
[26] Véronique Préat,et al. Topical Gene Transfer into Rat Skin Using Electroporation , 2004, Pharmaceutical Research.
[27] Chi-Hwa Wang,et al. Computer simulation of the delivery of etanidazole to brain tumor from PLGA wafers: comparison between linear and double burst release systems. , 2003, Biotechnology and bioengineering.
[28] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[29] Spyros K. Stamatelos,et al. Multiscale Imaging and Computational Modeling of Blood Flow in the Tumor Vasculature , 2012, Annals of Biomedical Engineering.
[30] Timothy W Secomb,et al. A mathematical model for cisplatin cellular pharmacodynamics. , 2003, Neoplasia.
[31] G. Bonadonna,et al. Chemotherapy of malignant lymphomas. , 1985, Seminars in oncology.
[32] R K Jain,et al. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.
[33] H. Skipper,et al. The effects of chemotherapy on the kinetics of leukemic cell behavior. , 1965, Cancer research.
[34] A. Einstein. Über die von der molekularkinetischen Theorie der Wärme geforderte Bewegung von in ruhenden Flüssigkeiten suspendierten Teilchen [AdP 17, 549 (1905)] , 2005, Annalen der Physik.
[35] Ze Lu,et al. Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy , 2014, The AAPS Journal.
[36] Stephen Clarke,et al. Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics , 2012, Clinical Pharmacokinetics.
[37] M F Flessner,et al. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. , 1985, The American journal of physiology.
[38] Byungkyu Kim,et al. Cell Stiffness Is a Biomarker of the Metastatic Potential of Ovarian Cancer Cells , 2012, PloS one.
[39] C. Erlichman,et al. Antineoplastic drug cytotoxicity in a human bladder cancer cell line: Implications for intravesical chemotherapy , 1987, Urological Research.
[40] J. Robinson,et al. Theoretical formulation of sustained-release dosage forms. , 1966, Journal of pharmaceutical sciences.
[41] Yasunari Miyagi,et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai , 2005, Gynecologic oncology.
[42] J G McVie,et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. , 1990, Cancer chemotherapy and pharmacology.
[43] Urs Giger-Pabst,et al. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.
[44] P. Sugarbaker,et al. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics , 2003, Cancer Chemotherapy and Pharmacology.
[45] M. Wientjes,et al. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. , 2001, The Journal of pharmacology and experimental therapeutics.
[46] S N Gardner,et al. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.
[47] Mahadevabharath R. Somayaji,et al. Prediction of convection-enhanced drug delivery to the human brain. , 2008, Journal of theoretical biology.
[48] H. Bartelink,et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. , 1998, European journal of cancer.
[49] Michel Simonet,et al. High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis , 2006, Annals of surgery.
[50] Abbas Shirinifard,et al. Ovarian Tumor Attachment, Invasion, and Vascularization Reflect Unique Microenvironments in the Peritoneum: Insights from Xenograft and Mathematical Models , 2013, Front. Oncol..
[51] S P Eriksen,et al. Mathematical model of sustained-release preparations and its analysis. , 1966, Journal of pharmaceutical sciences.
[52] G Milano,et al. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. , 1992, European journal of cancer.
[53] Wilson Mok,et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. , 2009, Biophysical journal.
[54] James A Glazier,et al. Multicell simulations of development and disease using the CompuCell3D simulation environment. , 2009, Methods in molecular biology.
[55] A. Oka,et al. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. , 1996, British Journal of Cancer.
[56] Kimberly R. Kanigel Winner,et al. Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. , 2016, Cancer research.
[57] N. Forbes,et al. Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response , 2010, British Journal of Cancer.
[58] Patrick Segers,et al. Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule , 2017, Drug delivery.
[59] Jesús A. Izaguirre,et al. From Genes to Organisms Via the Cell: A Problem-Solving Environment for Multicellular Development , 2007, Computing in Science & Engineering.
[60] Y. Maehara,et al. Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. , 1993, British Journal of Cancer.
[61] Timothy W Secomb,et al. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. , 2004, Neoplasia.
[62] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[63] Min Wu,et al. The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. , 2013, Journal of theoretical biology.
[64] Michael J Cima,et al. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[65] Michael F. Flessner,et al. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence , 2010, Nature Reviews Clinical Oncology.
[66] V. Devita,et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. , 1978, Cancer treatment reports.
[67] Christian Vanhove,et al. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model , 2015, Oncotarget.
[68] S. Bigler,et al. Is the Peritoneum a Significant Transport Barrier in Peritoneal Dialysis? , 2003, Peritoneal Dialysis International.
[69] Paolo P. Provenzano,et al. Collagen reorganization at the tumor-stromal interface facilitates local invasion , 2006, BMC medicine.